Riskpilot← Back to searchSign inGet full accessBIONOR LABORATORIES AS
ASActiveOrg 976814355Klosterøya Hollenderigata 3, 3732 SkienTechnical testing and analysis · NACE 7120Est. 19960 employeeswww.bionor.com
Revenue 2024
NOK 1,9M
+4% vs 2023
EBITDA margin
19.8%
+20% vs 2023
Equity ratio
19.2%
Financial strength
Net profit 2024
NOK 361K
+32% vs 2023
| Revenue | NOK 1,9M | +4% |
| EBITDA | NOK 371K | +20% |
| Net profit | NOK 361K | +32% |
| Total assets | NOK 1,7M | -17% |
| Equity | NOK 333K | +94% |
| Employees | 0 | — |
Legal name
BIONOR LABORATORIES AS
Org number
976814355
Legal form
Aksjeselskap
NACE code
7120 · Technical testing and analysis
Founded
1. juli 1996
Share capital
NOK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Klosterøya Hollenderigata 3, 3732 Skien
Website
www.bionor.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 915 | 1 771 | 1 967 | 1 967 | 0 | 2 289 | 2 246 | 1 704 | 1 805 | 1 770 | 1 412 | 1 737 | 1 720 | 1 915 | 1 631 | 1 795 | 1 873 |
| Staff expenses | −778 | −846 | −701 | −806 | −0 | −1 026 | −1 049 | −679 | −418 | −464 | −479 | −507 | −539 | −568 | −220 | −178 | −278 |
| EBITDA | 196 | 142 | 744 | 288 | 0 | 354 | 65 | 165 | 234 | 297 | 179 | 338 | 281 | 439 | 269 | 310 | 371 |
| Depreciation & amort. | −27 | −108 | −108 | −108 | −0 | −108 | −108 | −108 | −154 | −154 | −127 | −46 | −46 | −46 | −46 | −46 | −46 |
| EBIT | 169 | 34 | 636 | 180 | 0 | 246 | −42 | 57 | 81 | 143 | 52 | 292 | 235 | 393 | 223 | 264 | 325 |
| Net financials | −4 | −33 | −19 | −16 | 0 | 4 | −18 | −16 | −21 | −18 | 8 | −30 | 55 | −14 | 19 | 66 | 117 |
| Profit before tax | 166 | 1 | 617 | 163 | 0 | 250 | −60 | 41 | 60 | 125 | 59 | 262 | 289 | 379 | 242 | 330 | 442 |
| Tax | −0 | 0 | 174 | 50 | −0 | 70 | −0 | −0 | −0 | 34 | −2 | 58 | 64 | 60 | 53 | 56 | 80 |
| Net profit | 166 | 0 | 443 | 113 | 0 | 180 | −60 | 41 | 60 | 91 | 61 | 204 | 226 | 320 | 189 | 274 | 361 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 585 | 1 516 | 1 966 | 1 141 | — | 1 720 | 1 498 | 1 531 | 1 541 | 1 655 | 1 528 | 1 819 | 1 928 | 2 150 | 1 958 | 2 087 | 1 735 |
| Equity | 90 | 91 | 534 | 647 | — | 1 237 | 1 177 | 1 219 | 1 258 | 1 289 | 1 310 | 1 364 | 1 440 | 1 560 | 1 598 | 172 | 333 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 494 | 1 425 | 1 432 | 494 | 0 | 482 | 321 | 312 | 282 | 365 | 217 | 455 | 488 | 590 | 359 | 1 915 | 1 402 |
| Total debt | 1 494 | 1 425 | 1 432 | 494 | 0 | 482 | 321 | 312 | 282 | 365 | 217 | 455 | 488 | 590 | 359 | 1 915 | 1 402 |
EBITDA margin
19.8%
This company
15.8%
Market median
+25% vs market
20082024
Equity ratio
19.2%
This company
38.2%
Market median
-50% vs market
20082024
Return on equity
108.4%
This company
18.4%
Market median
+489% vs market
20082024
Net profit margin
19.3%
This company
8.1%
Market median
+138% vs market
20082024
Asset turnover
1.08×
This company
1.12×
Market median
+4% vs market
20082024
Debt / equity
4.20×
This company
0.62×
Market median
-577% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GH Contact Person | Contact Person | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2015 | — | — | |
| Chairman | 2015 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIONOR LABORATORIES AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gro Hauknes | Contact Person | 0 companies |
| Gunnar Arne Flåten | Board of Directors | 0 companies |
| Ellisiv Rogan | Chairman | 0 companies |